

FDA Clinical Review of

BLA 98-0369

Herceptin®
Trastuzumab
(rhuMAb HER2)

Date of Submission: May 4, 1998

Date of Approval: September 25, 1998

Sponsor: Genentech, Inc.

Food and Drug Administration
Center for Biologics Evaluation and Research

FDA Review Team

Product/Chair: Julia Goldstein, MD

Clinical/Primary: Susan Jerian, MD
Clinical/Secondary: Genevieve Schechter, MD

Statistical: Teresa Neeman, PhD

Pharm/Tox: M. David Green, PhD

Portions of the reviews of the statistical, product and pharmacology/toxicology sections have been included in the clinical review in order to improve the logical flow of the content and provide the reader with a comprehensive overview of the subject.

Table of Contents

Topic	Page
1.0 Background of the Product	06
2.0 Sponsor's Proposed Indication	09
3.0 Clinical Pharmacology Review	10
4.0 Methodology of the Clinical Review	14
5.0 Clinical Trial H0649g-Phase 2	18
5.1 Title H0649g	18
5.2 Study Design and Conduct H0649g	18
5.3 Results - Efficacy H0649g	21
5.4 Results - Safety H0649g	27
6.0 Clinical Trial H0648g-Phase 3	31
6.1 Title H0648g	31
6.2 Title H0659g	31
6.3 Study Design and Conduct H0648g	31
6.4 Study H0659g	36
6.5 Methodology of Data Review H0648g	37
6.6 Results - Efficacy H0648g	37
6.7 Results - Safety H0648g	60
7.0 Relationship Between Level of HER2/neu Protein Overexpression and Clinical Benefit	73
8.0 Overall Efficacy for all Phase 2 and 3 studies	77
9.0 Reviewer's Conclusions	79
10.0 Appendix A: Patient Summaries	83
11.0 Appendix B: Pharmacology/Toxicology	92
12.0 Appendix C: Abbreviations	96
13.0 Appendix D: Definitions	98
14.0 Appendix E: Questions for the Oncologic Drugs Advisory Committee Meeting September 2, 1998	100
15.0 Final FDA Clinical Reviewer Recommendation	105
Figure	Page
Figure 1. Kaplan-Meier Estimates Survival H0649g	27
Figure 2. Time to Progression, All Patients H0648g	50
Figure 3. Time to Progression, AC Patients H0648g	51
Figure 4. Time to Progression, Taxol Patients H0648g	52
Figure 5. Survival Plot, All Patients H0648g	56
Figure 6. Survival Plot, AC Patients H0648g	57
Figure 7. Survival Plot, Taxol Patients H0648g	58
Figure 8. Summary of Cardiotoxicity Events H0648g and H0649g	69
Figure 9. Kaplan-Meier Estimates of Cardiac Toxicities by Cumulative AC Dose	71

Figure		Page
Figure 10.	Kaplan-Meier Estimates of Cardiac Toxicities (3/4) by Cumulative AC Dose	71
Figure 11.	Time to Progression 2+ Patients H0648g and H0649g	75
Figure 12.	Time to Progression 3+ Patients H0648g and H0649g	76

Table		Page
Table 1.	Selection Criteria H0649g	19
Table 2.	Reasons for Discontinuation of Therapy H0649g	22
Table 3.	Demographics H0649g	24
Table 4.	Primary Endpoint H0649g - FDA derived data set	26
Table 5.	Secondary Endpoint H0649g - Sponsor derived data set	26
Table 6.	Adverse Events H0649g	28-30
Table 7.	Comparison of original and final protocol H0648g	33
Table 8.	Demographics H0648g	39
Table 9.	Sites of metastatic Disease H0648g - FDA analysis	40
Table 10.	Concomitant therapy by study arm H0648g	45
Table 11.	Cumulative dose for anthracyclines and paclitaxel H0648g	45
Table 12.	Patients who stopped therapy prior to completing 6 cycles of chemotherapy H0648g	46
Table 13.	Patients who completed chemotherapy and then stopped Herceptin H0648g	46
Table 14.	Reasons for stopping therapy H0648g	47
Table 15.	Time to Progression - Sponsor derived data set H0648g	49
Table 16.	Time to Progression - FDA derived data set H0648g	49
Table 17.	Response rate and duration of response - Sponsor derived data set H0648g	54
Table 18.	Response rate and duration of response - FDA derived data set H0648g	54
Table 19.	Time to Treatment Failure - Sponsor derived data set H0648g	55
Table 20.	Survival H0648g	55
Table 21.	Responding patients relative to IHC score of protein over-expression	60
Table 22.	Proportion of patients who had tumor response: 2+ vs 3+	60

Table 23.	Adverse events H0648g - Listing as percent of those enrolled and treated	61-62
Table 24.	Adverse events H0648g - Listing by number of moderate and severe events	63-64
Table 25.	Selected toxicity events - FDA derived data set H0648g	65
Table 26.	Profile/demographics of patients who developed cardiotoxicity H0648g	68
Table 27.	Incidence of cardiotoxicity class I-IV by cumulative dose range H0648g	70
Table 28.	Incidence of cardiotoxicity class III-IV by cumulative dose range H0648g	70
Table 29.	Percent of patients testing 2+ or 3+ by IHC H0648g and H0649g	73
Table 30.	Response rate by IHC score H0648g and H0649g	74
Table 31.	Median time to progression of 2+ vs 3+ patients enrolled on H0648g	74
Table 32.	Efficacy results for all Herceptin studies submitted to the BLA	78

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.